Clinical trial
A Phase 3b Clinical Study to Assess Whether Regular Administration of ADVATE in the Absence of Immunological Danger Signals Reduces the Incidence Rate of Inhibitors in Previously Untreated Patients With Hemophilia A
NCT01376700 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3b Clinical Study to Assess Whether Regular Administration of ADVATE in the Absence of Immunological Danger Signals Reduces the Incidence Rate of Inhibitors in Previously Untreated Patients With Hemophilia A
- Lead sponsor
- Baxalta now part of Shire
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- August 26, 2011
- Completion date
- November 16, 2012
- Enrollment
- 22 (actual)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.